Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies
2014; Wiley; Volume: 29; Issue: 14 Linguagem: Inglês
10.1002/mds.26105
ISSN1531-8257
Autores Tópico(s)Neurological diseases and metabolism
ResumoMovement DisordersVolume 29, Issue 14 p. 1707-1709 Editorial Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies Anthony E. Lang MD, FRCPC, Corresponding Author Anthony E. Lang MD, FRCPC Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital and the University of Torontocorrespondence to: Dr. AE Lang, Toronto western Hospital, 399 Bathurst St, 7 McLaughlin Wing, Toronto, ON, Canada, M5T 2S8; [email protected].Search for more papers by this author Anthony E. Lang MD, FRCPC, Corresponding Author Anthony E. Lang MD, FRCPC Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital and the University of Torontocorrespondence to: Dr. AE Lang, Toronto western Hospital, 399 Bathurst St, 7 McLaughlin Wing, Toronto, ON, Canada, M5T 2S8; [email protected].Search for more papers by this author First published: 10 November 2014 https://doi.org/10.1002/mds.26105Citations: 13Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of "heterogenous system degeneration". Trans Am Neurol Assoc 1963; 88: 25–29. 2Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333–358. 3Steele JC. Progressive supranuclear palsy. Brain 1972; 95: 693–704. 4Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270–279. 5Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord 2013; 19: 1149–1151. 6Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996; 47: 1–9. 7Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 29;80: 496–503. 8Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010 15;25: 357–362. 9Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014; 20: 525–529. 10Respondek G, Stamelou, M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicentre study of 100 definite cases. Mov Disord 2014; 29: 1758–1766. 11Weiner MW, Aisen PS, Jack CR, Jr, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202–211. 12Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis 2013; 36: 145–153. 13Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009 16;62: 42–52. 14Gardner RC, Boxer AL, Trujillo A, et al. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 2013; 73: 603–616. 15Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Natl Acad Sci U S A 2013; 110: 11606–11611. 16Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Munoz MJ, Troncoso J, Kayed R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun 2014; 2: 73. 17Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110: 9535–9540. 18Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. "Prion-like" templated misfolding in tauopathies. Brain Pathol 2013; 23: 342–349. 19Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007; 318: 930–936. 20Sanders DW, Kaufman SK, DeVos SL, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014; 82: 1271–1288. Citing Literature Volume29, Issue14December 2014Pages 1707-1709 ReferencesRelatedInformation
Referência(s)